Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
United Therapeutics Analyst Ratings and Price Targets | NASDAQ:UTHR | Benzinga
United Therapeutics Corp has a consensus price target of $375.73 based on the ratings of 15 analysts. The high is $600 issued by Oppenheimer on October 31, 2024. The low is $294 issued by JP Morgan on November 2, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JP Morgan, and Morgan Stanley on May 5, 2025, May 1, 2025, and May 1, 2025, respectively. With an average price target of $374.33 between HC Wainwright & Co., JP Morgan, and Morgan Stanley, there's an implied 18.19% upside for United Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Morgan Stanley
Wells Fargo
B of A Securities
1calculated from analyst ratings
Analyst Ratings for United Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/05/2025 | Buy Now | 34.19% | HC Wainwright & Co. | Andrew Fein57% | $425 → $425 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2025 | Buy Now | 10.51% | JP Morgan | Jessica Fye64% | $355 → $350 | Maintains | Overweight | Get Alert |
| 05/01/2025 | Buy Now | 9.88% | Morgan Stanley | Terence Flynn64% | $346 → $348 | Maintains | Equal-Weight | Get Alert |
| 04/25/2025 | Buy Now | -0.86% | Wells Fargo | Tiago Fauth44% | $395 → $314 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/21/2025 | Buy Now | 12.09% | JP Morgan | Jessica Fye64% | $357 → $355 | Maintains | Overweight | Get Alert |
| 04/21/2025 | Buy Now | -0.86% | B of A Securities | Greg Harrison46% | $314 → $314 | Upgrade | Underperform → Neutral | Get Alert |
| 02/27/2025 | Buy Now | 34.19% | HC Wainwright & Co. | Andrew Fein57% | $425 → $425 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 49.97% | UBS | Ashwani Verma47% | $415 → $475 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | -4.65% | Goldman Sachs | Chris Shibutani55% | $243 → $302 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 8.61% | Ladenburg Thalmann | Matthew Kaplan65% | $319 → $344 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 89.44% | Oppenheimer | Hartaj Singh46% | $575 → $600 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 26.29% | Argus Research | Jasper Hellweg68% | $360 → $400 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 34.19% | HC Wainwright & Co. | Andrew Fein57% | $400 → $425 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 26.29% | TD Cowen | Joseph Thome26% | $350 → $400 | Maintains | Buy | Get Alert |
| 09/23/2024 | Buy Now | 36.4% | Jefferies | Eun Yang33% | $315 → $432 | Maintains | Buy | Get Alert |
| 08/28/2024 | Buy Now | 81.55% | Oppenheimer | Hartaj Singh46% | $400 → $575 | Maintains | Outperform | Get Alert |
| 08/20/2024 | Buy Now | 19.98% | Wells Fargo | Tiago Fauth44% | $350 → $380 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 26.29% | HC Wainwright & Co. | Andrew Fein57% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | -11.59% | B of A Securities | Greg Harrison46% | $303 → $280 | Maintains | Underperform | Get Alert |
| 07/25/2024 | Buy Now | 26.29% | HC Wainwright & Co. | Andrew Fein57% | $300 → $400 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 10.51% | TD Cowen | Joseph Thome26% | $270 → $350 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 1.35% | Morgan Stanley | Terence Flynn64% | $310 → $321 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 16.82% | UBS | Ashwani Verma47% | $300 → $370 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 10.51% | Wells Fargo | Tiago Fauth44% | $325 → $350 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | -5.28% | JP Morgan | Jessica Fye64% | $280 → $300 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | -24.22% | Goldman Sachs | Chris Shibutani55% | $218 → $240 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | -5.28% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 26.29% | Oppenheimer | Hartaj Singh46% | $375 → $400 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 2.61% | Wells Fargo | Tiago Fauth44% | $309 → $325 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | -2.75% | Wedbush | Liana Moussatos74% | $308 → $308 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | -5.28% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2024 | Buy Now | -32.12% | Goldman Sachs | Chris Shibutani55% | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
| 02/05/2024 | Buy Now | 4.19% | Leerink Partners | Roanna Ruiz36% | → $330 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | Buy Now | -7.17% | JP Morgan | Jessica Fung38% | $290 → $294 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -0.86% | Morgan Stanley | Terence Flynn64% | $318 → $314 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -2.75% | Wedbush | Liana Moussatos74% | $307 → $308 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | 0.4% | Morgan Stanley | Terence Flynn64% | $316 → $318 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -15.38% | Ladenburg Thalmann | Matthew Kaplan65% | $256 → $268 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -3.07% | Wedbush | Liana Moussatos74% | $305 → $307 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -5.28% | HC Wainwright & Co. | Andrew Fein57% | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | Buy Now | -19.17% | Ladenburg Thalmann | Matthew Kaplan65% | $285 → $256 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | -11.59% | Argus Research | Jasper Hellweg68% | $300 → $280 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | -2.12% | UBS | Ashwani Verma47% | $330 → $310 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | -0.23% | Morgan Stanley | Terence Flynn64% | $320 → $316 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -11.59% | JP Morgan | Jessica Fung38% | $265 → $280 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 1.04% | Morgan Stanley | Terence Flynn64% | $330 → $320 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -5.28% | HC Wainwright & Co. | Andrew Fein57% | → $300 | Reiterates | → Buy | Get Alert |
| 01/11/2023 | Buy Now | -5.28% | Argus Research | Jasper Hellweg68% | $250 → $300 | Maintains | Buy | Get Alert |
| 12/06/2022 | Buy Now | 4.19% | Morgan Stanley | Terence Flynn64% | $322 → $330 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 1.04% | UBS | Ashwani Verma47% | → $320 | Initiates | → Buy | Get Alert |
| 12/05/2022 | Buy Now | -27.38% | Goldman Sachs | Chris Shibutani55% | → $230 | Initiates | → Sell | Get Alert |
| 11/03/2022 | Buy Now | -16.33% | JP Morgan | Jessica Fye64% | $240 → $265 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 1.67% | Morgan Stanley | Terence Flynn64% | $288 → $322 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 18.4% | Oppenheimer | Hartaj Singh46% | $325 → $375 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | -5.28% | HC Wainwright & Co. | Andrew Fein57% | $255 → $300 | Maintains | Buy | Get Alert |
| 10/11/2022 | Buy Now | -9.07% | Morgan Stanley | Terence Flynn64% | → $288 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for United Therapeutics (UTHR) stock?
The latest price target for United Therapeutics (NASDAQ:UTHR) was reported by HC Wainwright & Co. on May 5, 2025. The analyst firm set a price target for $425.00 expecting UTHR to rise to within 12 months (a possible 34.19% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ:UTHR) was provided by HC Wainwright & Co., and United Therapeutics reiterated their buy rating.
When was the last upgrade for United Therapeutics (UTHR)?
The last upgrade for United Therapeutics Corp happened on April 21, 2025 when B of A Securities raised their price target to $314. B of A Securities previously had an underperform for United Therapeutics Corp.
When was the last downgrade for United Therapeutics (UTHR)?
The last downgrade for United Therapeutics Corp happened on April 25, 2025 when Wells Fargo changed their price target from $395 to $314 for United Therapeutics Corp.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on May 5, 2025 so you should expect the next rating to be made available sometime around May 5, 2026.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a reiterated with a price target of $425.00 to $425.00. The current price United Therapeutics (UTHR) is trading at is $316.72, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
